

Edgar Filing: UNITED THERAPEUTICS CORP - Form SC 13G

UNITED THERAPEUTICS CORP  
Form SC 13G  
November 05, 2009

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

United Therapeutics Corporation

-----  
(Name of Issuer)

COMMON STOCK

-----  
(Title of Class of Securities)

US91307C1027

-----  
(CUSIP Number)

October 23rd, 2009

-----  
(Date of Event Which Requires Filing of this Statement)

Check appropriate box to designate the rule pursuant to which this  
Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed  
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of  
1934 ("Act") or otherwise subject to the liabilities of that section of the Act  
but shall be subject to all other provisions of the Act (however, see the  
Notes).

-----  
1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

PICTET FUNDS - BIOTECH

-----  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) ☐

(b) ☒

-----  
3 SEC USE ONLY

-----  
4 CITIZENSHIP OR PLACE OF ORGANIZATION

Luxembourg

-----  
5 SOLE VOTING POWER

2'737'680

Edgar Filing: UNITED THERAPEUTICS CORP - Form SC 13G

-----  
NUMBER OF 6 SHARED VOTING POWER  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH 7 SOLE DISPOSITIVE POWER  
REPORTING  
PERSON  
WITH  
8 SHARED DISPOSITIVE POWER  
-----

-----  
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2'737'680  
-----

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*  
-----

|\_|

-----  
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.15%  
-----

12 TYPE OF REPORTING PERSON\*

INVESTMENT FUND  
-----

\*SEE INSTRUCTIONS BEFORE FILLING OUT

Item 1.

- (a) Name of Issuer: United Therapeutics Corporation  
(b) Address of Issuer's Principal Executive Offices:

1110 Spring Street  
Silver Spring, MD 20910  
United States

Item 2.

- (a) Name of Person Filing:  
PICTET FUNDS - BIOTECH  
(b) Address of Principal Business Office or, if none, Residence:  
Luxembourg  
(c) Citizenship: Luxembourg  
(d) Title of Class Securities: Common Stock  
(e) CUSIP Number: N.A.

Item 3.

Not applicable.

Item 4. Ownership

Edgar Filing: UNITED THERAPEUTICS CORP - Form SC 13G

- (a) Amount Beneficially Owned: 2'737'680
- (b) Percent of Class: 5.15%.
- (c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote:

(ii) shared power to vote or to direct the vote:

(iii) sole power to dispose or to direct the disposition of:

(iv) shared power to dispose or to direct the disposition of:

Item 5. Ownership of Five Percent or Less of a Class

Not applicable.

Item 6.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of the Group

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, We certify that the information set forth in this statement is true, complete and correct.

Date: November 5th, 2009

Charles Vallee  
-----

Claudy Huart  
-----

-----

-----

om">

**(Commission**

**File Number)**

**(IRS Employer**

**Identification No.)**

**800 Boylston Street, Suite 1900, Boston, Massachusetts 02199**

**(Address of Principal Executive Offices) (Zip Code)**

**(617) 236-3300**

**(Registrants telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition.**

The information in this Item 2.02 - Results of Operations and Financial Condition is being furnished. Such information, including Exhibits 99.1 and 99.2 hereto, shall not be deemed filed for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section. The information in this Item 2.02, including Exhibits 99.1 and 99.2, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.

On January 31, 2017, Boston Properties, Inc. (the Company), the general partner of Boston Properties Limited Partnership, issued a press release announcing its financial results for the fourth quarter of 2016. That press release referred to certain supplemental information that is available on the Company's website. The text of the supplemental information and the press release are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

(d) *Exhibits.*

Exhibit No.	Description
*99.1	Boston Properties, Inc. Supplemental Operating and Financial Data for the quarter ended December 31, 2016.
*99.2	Press release dated January 31, 2017.

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned hereunto duly authorized.

BOSTON PROPERTIES, INC.

By: /s/ Michael E. LaBelle  
Michael E. LaBelle  
Executive Vice President, Chief Financial  
Officer and Treasurer

BOSTON PROPERTIES LIMITED  
PARTNERSHIP

By: Boston Properties, Inc., its General  
Partner

By: /s/ Michael E. LaBelle  
Michael E. LaBelle  
Executive Vice President, Chief Financial  
Officer and Treasurer

Date: January 31, 2017

**EXHIBIT INDEX**

Exhibit No.	Description
*99.1	Boston Properties, Inc. Supplemental Operating and Financial Data for the quarter ended December 31, 2016.
*99.2	Press release dated January 31, 2017.

\* Filed herewith.